Nature15 年
Polymyositis therapy: is there a place for IL-6 blockade?
New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis. Elevated ...
Business Insider1 个月
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically ...
来自MSN1 个月
Study uncovers key factors in myositis-induced muscle weakness
A study has shed new light on the mechanisms behind idiopathic inflammatory myopathies (myositis), a group of systemic autoimmune disorders known for causing severe muscle weakness, fatigue ...
manilatimes1 个月
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is ...
Lupus Foundation of America3 天
Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...
Medscape6 天
Novel Autoantibodies Identified in Patients with Necrotizing Myopathy
The chronic inflammatory myopathies are idiopathic, meaning they have no known cause. They are thought to be autoimmune disorders, in which the body's white blood cells (that normally fight ...
Yahoo Finance1 个月
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...